VBI Vaccines Inc (NASDAQ:VBIV) shares gapped down before the market opened on Wednesday . The stock had previously closed at $0.84, but opened at $0.86. VBI Vaccines shares last traded at $0.83, with a volume of 91,401 shares.
Several analysts have recently commented on VBIV shares. Raymond James started coverage on shares of VBI Vaccines in a report on Thursday, November 14th. They issued an “outperform” rating and a $3.00 target price for the company. Zacks Investment Research lowered shares of VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Wednesday, August 21st. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. VBI Vaccines has a consensus rating of “Buy” and a consensus price target of $3.81.
The stock has a market cap of $160.13 million, a P/E ratio of -0.88 and a beta of 0.79. The business has a 50 day simple moving average of $0.63 and a 200-day simple moving average of $0.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.84 and a current ratio of 1.88.
VBI Vaccines (NASDAQ:VBIV) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.02). The business had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.90 million. VBI Vaccines had a negative return on equity of 70.54% and a negative net margin of 1,458.97%. On average, sell-side analysts predict that VBI Vaccines Inc will post -0.47 earnings per share for the current fiscal year.
In other news, CEO Jeff Baxter bought 150,000 shares of the firm’s stock in a transaction on Monday, September 30th. The stock was acquired at an average cost of $0.50 per share, with a total value of $75,000.00. Following the completion of the transaction, the chief executive officer now directly owns 608,255 shares of the company’s stock, valued at approximately $304,127.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Perceptive Advisors Llc bought 20,000,000 shares of the stock in a transaction on Monday, September 23rd. The stock was purchased at an average price of $0.50 per share, for a total transaction of $10,000,000.00. The disclosure for this purchase can be found here. Insiders have purchased 30,212,000 shares of company stock valued at $15,105,440 in the last 90 days. 10.50% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. lifted its stake in VBI Vaccines by 2,089.1% in the 2nd quarter. BlackRock Inc. now owns 4,224,285 shares of the biopharmaceutical company’s stock worth $4,943,000 after purchasing an additional 4,031,318 shares in the last quarter. Perceptive Advisors LLC grew its stake in VBI Vaccines by 8.4% during the 2nd quarter. Perceptive Advisors LLC now owns 25,951,556 shares of the biopharmaceutical company’s stock worth $24,607,000 after buying an additional 2,000,000 shares during the last quarter. Sabby Management LLC purchased a new position in VBI Vaccines in the 3rd quarter valued at $413,000. Squarepoint Ops LLC bought a new position in VBI Vaccines during the 3rd quarter worth approximately $214,000. Finally, General American Investors Co. Inc. boosted its holdings in shares of VBI Vaccines by 23.2% in the 2nd quarter. General American Investors Co. Inc. now owns 2,174,264 shares of the biopharmaceutical company’s stock valued at $2,544,000 after buying an additional 409,800 shares during the period. 40.91% of the stock is owned by institutional investors.
VBI Vaccines Company Profile (NASDAQ:VBIV)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
See Also: What is range trading?
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.